ACUTE RENAL GRAFT REJECTION W/ BMY-42215-1 (15-DEOXYSPERGUALIN TRIHYDROCHLORIDE)

BMY-42215-1（15-脱氧精胍菌素三盐酸盐）引起的急性肾移植排斥

• 批准号: 6244690
• 负责人: ALAN B LEICHTMAN
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244690
• 关键词: clinical research; combination chemotherapy; corticosteroids; drug screening /evaluation; graft versus host disease; guanidines; human subject; human therapy evaluation; immunosuppressive; intravenous administration; kidney transplantation; outcomes research; transplant rejection

This study is designed to assess the efficacy and safety of BMY-42215-1 (deoxyspergualin, DSG) plus intravenous pulse corticosteroids compared with placebo plus intravenous pulse corticosteroids in the treatment of patients with acute renal allograft rejection episodes. The intent of the study is to establish whether the addition of 15-deoxyspergualin- trichloride to corticosteroids will improve the outcomes of rejection therapy and reduce the need for treatment with antilymphocyte agents such as OKT3 or ATGAM.

本研究旨在评估BMY-42215-1的疗效和安全性 （脱氧精胍菌素，DSG）加静脉冲击皮质类固醇比较 安慰剂加静脉冲击皮质类固醇治疗 急性肾移植排斥反应患者。 的意图 该研究是为了确定是否添加15-脱氧精胍灵- 糖皮质激素治疗可改善排斥反应的结局 治疗和减少对抗淋巴细胞剂治疗的需要 例如OKT 3或ATGAM。